| Dr John H Mcvicker, MD | |
|
1725 E Boulder St, Suite 101, Colorado Springs, CO 80909-5768 | |
| (719) 365-6300 | |
| (719) 365-6094 |
| Full Name | Dr John H Mcvicker |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 43 Years |
| Location | 1725 E Boulder St, Colorado Springs, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811917701 | NPI | - | NPPES |
| 01282375 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 28237 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uch-memorial Health System | Colorado springs, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Poudre Valley Medical Group Llc | 9638208549 | 1605 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.
There is an enormous amount of interest in using meditation as a form of therapy to cope with a variety of modern-day health problems, especially hypertension, stress and chronic pain, but the majority of evidence that seems to support this notion is anecdotal, or it comes from poor quality studies, say Maria Ospina and Kenneth Bond, researchers at the University of Alberta/Capital Health Evidence-based Practice Center in Edmonton, Canada.
QLT Inc. today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.
Health Discovery Corporation announced today that the Company has received the final payment that was due under the agreement that settled the Company's patent infringement lawsuit against Vermillion, formerly known as Ciphergen Biosystems, Inc.
› Verified 3 days ago
| Entity Name | Poudre Valley Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366763260 PECOS PAC ID: 9638208549 Enrollment ID: O20100602000122 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.
There is an enormous amount of interest in using meditation as a form of therapy to cope with a variety of modern-day health problems, especially hypertension, stress and chronic pain, but the majority of evidence that seems to support this notion is anecdotal, or it comes from poor quality studies, say Maria Ospina and Kenneth Bond, researchers at the University of Alberta/Capital Health Evidence-based Practice Center in Edmonton, Canada.
QLT Inc. today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.
Health Discovery Corporation announced today that the Company has received the final payment that was due under the agreement that settled the Company's patent infringement lawsuit against Vermillion, formerly known as Ciphergen Biosystems, Inc.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John H Mcvicker, MD 8890 N Union Blvd, Ste 160, Colorado Springs, CO 80920-7799 Ph: (719) 365-9950 | Dr John H Mcvicker, MD 1725 E Boulder St, Suite 101, Colorado Springs, CO 80909-5768 Ph: (719) 365-6300 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.
There is an enormous amount of interest in using meditation as a form of therapy to cope with a variety of modern-day health problems, especially hypertension, stress and chronic pain, but the majority of evidence that seems to support this notion is anecdotal, or it comes from poor quality studies, say Maria Ospina and Kenneth Bond, researchers at the University of Alberta/Capital Health Evidence-based Practice Center in Edmonton, Canada.
QLT Inc. today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.
Health Discovery Corporation announced today that the Company has received the final payment that was due under the agreement that settled the Company's patent infringement lawsuit against Vermillion, formerly known as Ciphergen Biosystems, Inc.
› Verified 3 days ago
Michael W Brown, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 2312 N Nevada Ave, Suite 100, Colorado Springs, CO 80907 Phone: 719-473-3272 Fax: 719-389-1191 | |
Dr. Allan Douglas Nanney Iii, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2222 N Nevada Ave Ste 5001, Colorado Springs, CO 80907 Phone: 719-776-3580 Fax: 719-776-3599 | |
Mr. Shervin Rahimpour, Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 5544 Saxon Ln, Colorado Springs, CO 80918 Phone: 719-290-2827 | |
Dr. Rahul Singh, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1725 E Boulder St Ste 101, Colorado Springs, CO 80909 Phone: 719-365-6300 Fax: 719-365-6094 | |
Nicholas Maurio, NP Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 8540 Scarborough Dr Ste 100, Colorado Springs, CO 80920 Phone: 719-955-4200 Fax: 719-365-7667 | |
Donald James Sceats Jr., M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 2312 N Nevada Ave, Suite 100, Colorado Springs, CO 80907 Phone: 719-473-3272 Fax: 719-389-1191 | |
Dr. Todd Palmer Thompson, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 1725 E Boulder St, Suite 101, Colorado Springs, CO 80909 Phone: 719-365-6300 Fax: 719-365-6094 |